Erasca touts early colorectal cancer data, trims a slate of trials and preclinical programs to refine focus

Amber Tong

Erasca believes it’s secured the early clinical data to show one of its targeted therapies holds promise as a “backbone” for drug combinations, particularly for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Erasca touts early colorectal cancer data, trims a slate of trials and preclinical programs to refine focus

Amber Tong

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

China’s biotech market is staging a comeback that US biotech can only wish for

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Genentech vet launches ADC startup with $20M

Bristol Myers' schizophrenia drug fails Phase 3 trial for adjunctive treatment

Ascletis posts puzzling Phase 1 update on obesity pill

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Eras­ca touts ear­ly col­orec­tal can­cer da­ta, trims a slate of tri­als and pre­clin­i­cal pro­grams to re­fine fo­cus

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Erasca touts early colorectal cancer data, trims a slate of trials and preclinical programs to refine focus